ResMed Executive Files Rule 144 Notice for Routine Share Sales

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an announcement.

ResMed Inc. has disclosed that company officer Brett Sandercock plans to sell 1,000 common shares under Rule 144, with the transaction arranged through Fidelity Brokerage Services and scheduled around March 2, 2026. The filing also notes that Sandercock, acting under a pre-established Rule 10b5-1 trading plan adopted in February 2025, has sold a total of 2,000 shares over the past three months, signaling routine executive share disposals rather than a newly opportunistic move.

These planned sales stem from the vesting of restricted stock granted as compensation in November 2023, reflecting ongoing equity-based remuneration practices at the company. While the volumes involved are small relative to ResMed’s more than 145 million outstanding shares, they provide investors with transparency into insider trading activity and confirm the executive’s assertion that he is not acting on any undisclosed adverse information about the firm’s current or prospective operations.

The most recent analyst rating on (AU:RMD) stock is a Hold with a A$39.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a U.S.-based medical technology company focused on developing and manufacturing devices and software solutions for the diagnosis, treatment, and management of sleep-disordered breathing and other chronic respiratory conditions. Its products are primarily used in home and clinical settings, and its shares are listed on the NYSE.

Average Trading Volume: 1,091,888

Technical Sentiment Signal: Hold

Current Market Cap: A$52.86B

For an in-depth examination of RMD stock, go to TipRanks’ Overview page.